Four bottlenecks.
Four precision solutions.
A single generalized user persona is insufficient. The platform's progressive tier system is specifically architected to serve different stakeholders at their highest-cost operational failure point.
Extremely limited capital runway. A biotech startup cannot afford to spend $250,000 and six months of wet-lab time synthesizing a molecular candidate that fails its first animal toxicity check. Every failed physical synthesis iteration is an existential event.
- Use the FDC Designer and ADMET Profiler to design, test, and discard thousands of unviable chemical structures digitally — in minutes, not months.
- Run heavy virtual screenings on ExergyNet Secure Compute at 88.6% below centralized cloud rates, preserving cash runway for high-probability physical trials only.
- Every blueprint exits simulation with a ZK-STARK proof receipt and Merkle-anchored provenance — IP-protected from day one, before any physical synthesis begins.
Traditional computational platforms threaten the CRO business model by positioning themselves as lab replacements. CROs need automated, high-precision experimental designs that translate computational theories into high-yield physical test protocols — not competition.
- MetalDrug does not threaten the CRO. We are the upstream logic layer that makes their physical work more valuable and reproducible.
- The Experimental Protocol Generator outputs exact, step-by-step physical assay parameters from validated blueprints: Caco-2 seeding density, Western blot parameters, ELISA targets, chromatography settings.
- CROs convert from generic assay providers into high-confidence validation endpoints for blueprint predictions — reducing false starts and increasing sponsor confidence in their data.
The Loss of Exclusivity (LOE) cliff — $47B in revenue at risk as of 2026 — forces large pharma to acquire early-stage biotech assets aggressively. The critical failure mode: they cannot verify the integrity of AI-generated computational data or distinguish credible simulation portfolios from fabricated ones during due diligence.
- The Blueprint Ledger provides the first mathematically auditable due-diligence framework — every simulation record is backed by unforgeable, on-chain RISC Zero ZK-STARK receipts.
- Acquirers audit the asset's complete developmental timeline, verifying that results have not been altered or back-dated post-hoc. No trust required — only cryptographic proof.
- IP validation is possible without accessing proprietary molecular structure data — ZK proofs confirm execution integrity while maintaining full confidentiality.
Translating advanced computational predictions into the formal, legalistic document architecture required by FDA's 2025 AI Guidance and FDAMA 3.0. Manual drafting of eCTD nonclinical summaries from raw simulation data can take months and significant legal overhead.
- The eCTD Document Compiler takes verified, on-chain simulation records and auto-generates structured, editable drafts of eCTD Module 2.4 (Nonclinical Overview) and Module 2.6 (Nonclinical Written Summaries).
- The Human-in-the-Loop Feedback Ledger captures specialist edits and continuously reduces the formatting entropy of future document generations — the system learns from every review cycle.
- Every compiled document links back to its ZK-STARK-verified source simulation, providing regulators with a complete, auditable causal chain from in silico data to formal submission.
2.0 NAM-compatible output
"If you're building the future of therapeutics — we're building the logic behind it."
Join our ecosystem. Tell us which stakeholder profile fits your team and we will align the correct tier, licensing structure, and onboarding path.